Drug & supplement interaction

Bupleurum + Nivolumab, Relatlimab-rmbw

Nivolumab, Relatlimab-rmbw brand name: Opdualag.

No Known Interaction
The bottom line No known interaction

We found no known interaction between Bupleurum and Nivolumab, Relatlimab-rmbw in our sources. Absence of a documented interaction is not the same as proven safety, and does not guarantee one does not exist. Do not start, stop, or change a medication or supplement based on this page; confirm with your pharmacist or doctor first. Additionally, although there is no interaction, the two are separately associated with some of the same side effects, which would make a new symptom harder to attribute to one or the other.

Know someone taking this? Share
Interaction report

Bupleurum and Nivolumab, Relatlimab-rmbw

We checked these two against our interaction database. Here is what we found.

No Known Interaction Found

We did not find a documented interaction between Nivolumab, Relatlimab-rmbw and Bupleurum in our sources. This does not guarantee that the combination is completely free of risk — there is often limited research on supplements and herbal products, especially around drug interactions.

If you decide to take both, the practical routine is simple: add one new thing at a time and note the date you started it. If the combination is going to disagree with you, it usually shows in the first days to a couple of weeks — and a start date turns “I’ve been feeling off” into something a pharmacist can actually work with. Do not stop a prescribed medicine on your own.

Always talk with your pharmacist or doctor before making changes to your medications or supplements, particularly if you take several medications or have an ongoing health condition.

Bupleurum safety at a glance

Bupleurum overall Use caution Generally used short-term in formulas, but it has been linked to rare lung and liver problems and quality varies.
Pregnancy Avoid Not enough safety information, so it is best avoided during pregnancy.
Breastfeeding Avoid Not enough safety information, so it is best avoided while breastfeeding.

Safety guidance is general; always confirm with your pharmacist or doctor for your situation.

Still wondering about combining Nivolumab, Relatlimab-rmbw and Bupleurum? Ask Dr. Brian Staiger, PharmD, BCPS directly ›
Keep it in perspective

Bupleurum Does Interact With Other Medications

Bupleurum has 327 moderate known drug interactions in our database — Nivolumab, Relatlimab-rmbw isn’t one of them. If you take anything else, check it against the full list below.

Taking anything else?

Check Another of Your Medications Against Bupleurum

Covers the 2,830 medications we’ve checked against Bupleurum. Pick one to open its full report.

What to actually watch for

No Interaction Found — But Data Suggests Bupleurum and Nivolumab, Relatlimab-rmbw May Share Several of the Same Side Effects

This is not an interaction. Neither one changes how your body handles the other, and nothing here says they react together. What our sources do show is that each has separately been linked to the effects below — so taking both can make those effects more likely to turn up, and harder to pin on one or the other if they do. One of them is worth acting on rather than waiting out — marked below.

  • A higher chance of infection Worth acting on Additional detail

    Bupleurum

    “Orally, combination products containing bupleurum have been reported to cause eosinophilic pneumonia, pulmonary edema, and multiple cases of pneumonitis. A specific combination product (sho-saiko-to), used in combination with interferon-alpha in patients with chronic active hepatitis, has also been associated with multiple cases of pneumonitis.”

    Bupleurum · Natural Medicines adverse-effect record, reported in hepatitis.

    6 sources cited
    1. 354. Kobashi Y, Nakajima M, Niki Y, Matsushima T. [A case of acute eosinophilic pneumonia due to Sho-saiko-to]. Nippon Kyobu Shikkan Gakkai Zasshi 1997;35:1372-7.
    2. 361. Miyazaki E, Ando M, Ih K, et al. [Pulmonary edema associated with the Chinese medicine shosaikoto]. Nihon Kokyuki Gakkai Zasshi 1998;36:776-80.
    3. 355. Wada Y, Kubo M. [Acute lymphoblastic leukemia complicated by type C hepatitis during treatment and further by acute interstitial pneumonia due to sho-saiko-to in 7-year-old]. Arerugi 1997;46:1148-55.
    4. 356. Sato A, Toyoshima M, Kondo A, et al. [Pneumonitis induced by the herbal medicine Sho-saiko-to in Japan]. Nippon Kyobu Shikkan Gakkai Zasshi 1997;35:391-5.
    5. 357. Daibo A, Yoshida Y, Kitazawa S, et al. [A case of pneumonitis and hepatic injury caused by a herbal drug (sho-saiko-to)]. Nippon Kyobu Shikkan Gakkai Zasshi 1992;30:1583-8.
    6. 37404. Sugiyama H, Nagai M, Kotajima F, and et al. [A case of interstitial pneumonia with chronic hepatitis C following interferon-alfa and sho-saiko-to therapy]. Arerugi 1995;44(7):711-714.

    Nivolumab, Relatlimab-rmbw

    Listed in the ADVERSE REACTIONS section of the FDA label for Nivolumab, Relatlimab-rmbw. Read the label on DailyMed ›

  • Reduced appetite / Nausea Additional detail

    Bupleurum

    “Orally, a specific bupleurum-containing combination product (sho-saiko-to) has been reported to cause nausea, anorexia, and abdominal fullness. It is unclear if these adverse effects are due to bupleurum, other ingredients, or the combination.”

    Bupleurum · Natural Medicines adverse-effect record, reported in anorexia.

    1 source cited
    1. 37391. Hirayama, C., Okumura, M., Tanikawa, K., and et al. A multicenter randomized controlled clinical trial of Shosaiko-to in chronic active hepatitis. Gastroenterol Jpn 1989;24(6):715-719. PubMed

    Nivolumab, Relatlimab-rmbw

    Listed in the ADVERSE REACTIONS section of the FDA label for Nivolumab, Relatlimab-rmbw. Read the label on DailyMed ›

  • Swelling Additional detail

    Bupleurum

    Recorded for Bupleurum in the same Natural Medicines adverse-effect record shown under A higher chance of infection above.

    Nivolumab, Relatlimab-rmbw

    Listed in the ADVERSE REACTIONS section of the FDA label for Nivolumab, Relatlimab-rmbw. Read the label on DailyMed ›

  • Tiredness Additional detail

    Bupleurum

    “Orally, a specific bupleurum-containing combination product (sho-saiko-to) has been reported to cause fatigue and paresthesia. It is unclear if these adverse effects are due to bupleurum, other ingredients, or the combination.”

    Bupleurum · Natural Medicines adverse-effect record, reported in fatigue.

    1 source cited
    1. 37391. Hirayama, C., Okumura, M., Tanikawa, K., and et al. A multicenter randomized controlled clinical trial of Shosaiko-to in chronic active hepatitis. Gastroenterol Jpn 1989;24(6):715-719. PubMed

    Nivolumab, Relatlimab-rmbw

    Listed in the ADVERSE REACTIONS section of the FDA label for Nivolumab, Relatlimab-rmbw. Read the label on DailyMed ›

Reported for Bupleurum but not commonly for Nivolumab, Relatlimab-rmbw: numbness or tingling and liver problems.

Effects for Nivolumab, Relatlimab-rmbw come from the ADVERSE REACTIONS section of its FDA label; effects for Bupleurum come from the Natural Medicines adverse-effect record, quoted above. Wording is matched across sources by our own clinical vocabulary, so treat this as a prompt to pay attention, not a diagnosis.

One more smart check

Taking Bupleurum as Part of a Dietary Supplement Product? Check It for Interactions

We hold 89 real supplement products containing Bupleurum, each one broken down to its full ingredient list — and combination products often carry several ingredients besides Bupleurum. Even though Bupleurum itself has no known interaction with Nivolumab, Relatlimab-rmbw, another ingredient on your label might. Find your product and we’ll check every ingredient on its label:

How much people look this up

Where Bupleurum and Nivolumab, Relatlimab-rmbw Sit Against Everything Else

Out of every supplement and medication people look up on HelloPharmacist, here is where these two land this week — and which way each has been moving.

Supplement Bupleurum
Top half

#396 of 1,452 supplements looked up here in the last 7 days

29 days ago today
Medication Nivolumab, Relatlimab-rmbw
Steady interest

#2,790 of 2,830 medications looked up here in the last 7 days

29 days ago today

Position among everything looked up on this site, not a measure of how commonly either one is used or how important it is. A supplement can climb this list because of a news story. It counts every request to the page, automated ones included, and nothing here identifies anyone.

Where does our data come from?
  • Source: the Natural Medicines (TRC Healthcare) clinical database — the evidence-graded professional reference for herb & supplement interactions.
  • Citation library: 103,510 references behind our interaction content, 65,311 of them resolved to verified PubMed/DOI sources. See every Bupleurum reference on this page ↓
  • Freshness: we automatically re-check this combination every week — this pair was last verified September 13, 2026. The Bupleurum and Nivolumab, Relatlimab-rmbw records this page draws on were last updated July 10, 2026.
  • What “no known interaction” means: no documented interaction in the sources above — not a guarantee of safety. Supplements are studied far less than prescription drugs, so we say exactly what the evidence supports, and nothing more.
Data structure & sourcing designed and verified by .
Supplement

About Bupleurum

What is Bupleurum?

Bupleurum
  • Liver and digestive support
  • Cold, flu, and fever
  • Inflammation
  • Stress and mood
  • Immune support

Bupleurum (Chai Hu) is a root used in traditional Chinese medicine, usually as part of multi-herb formulas, for liver, digestive, and fever-related complaints. High-quality human evidence for its benefits is limited, and it has been linked to lung and liver problems in some reports, so use it cautiously and only under professional guidance.

Bupleurum chinense · Apiaceae · Root · Capsules, tablets, dried root, teas, tinctures, and traditional Chinese herbal formulas

An interaction check asks whether these two react with each other — it does not ask whether Bupleurum is a good idea for someone in your situation. Here is what our Bupleurum record says about it on its own.

Bupleurum: dosing

There is no well-established standard dose of Bupleurum. Do not exceed the recommended amount, and avoid long-term use without professional guidance.

From our Bupleurum monograph — the full record covers uses, side effects and every documented interaction.

Read the full Bupleurum monograph & all interactions
Medication

About Nivolumab and relatlimab-rmbw

What Is Nivolumab and relatlimab-rmbw Used For?

Brand name: Opdualag

Opdualag is approved to treat unresectable or metastatic melanoma — melanoma that cannot be surgically removed or has spread to other parts of the body. It is approved for adults and for pediatric patients 12 years of age or older who weigh at least 40 kg (about 88 lbs).

A safe and effective dose for patients younger than 12, or for those 12 and older who weigh less than 40 kg, has not been established.

See full Nivolumab and relatlimab-rmbw drug information
Keep checking

Other Drugs & Bupleurum

Browse every other medication we’ve checked against Bupleurum — both the ones with a known interaction and the ones without. Select any drug for the full detail.

0Major
327Moderate
0Minor
2,502No known interaction
Moderate

327 interactions

Showing 60 of 327 moderate interactions — see all 327 on the Bupleurum page.

No interaction 2,502 drugs checked — show the list
Evidence & sources

Bupleurum References

The 17 references that drive our Bupleurum monograph and interaction data, from the evidence-graded Natural Medicines (TRC Healthcare) database. Citations with a link open the study on PubMed or the publisher’s site.

  1. Kobashi Y, Nakajima M, Niki Y, Matsushima T. [A case of acute eosinophilic pneumonia due to Sho-saiko-to]. Nippon Kyobu Shikkan Gakkai Zasshi 1997;35:1372-7.
  2. Wada Y, Kubo M. [Acute lymphoblastic leukemia complicated by type C hepatitis during treatment and further by acute interstitial pneumonia due to sho-saiko-to in 7-year-old]. Arerugi 1997;46:1148-55.
  3. Sato A, Toyoshima M, Kondo A, et al. [Pneumonitis induced by the herbal medicine Sho-saiko-to in Japan]. Nippon Kyobu Shikkan Gakkai Zasshi 1997;35:391-5.
  4. Daibo A, Yoshida Y, Kitazawa S, et al. [A case of pneumonitis and hepatic injury caused by a herbal drug (sho-saiko-to)]. Nippon Kyobu Shikkan Gakkai Zasshi 1992;30:1583-8.
  5. Sugiyama H, Nagai M, Kotajima F, et al. [A case of interstitial pneumonia with chronic hepatitis C following interferon-alfa and sho-saiko-to therapy]. Arerugi 1995;44:711-4.
  6. Ishizaki T, Sasaki F, Ameshima S, et al. Pneumonitis during interferon and/or herbal drug therapy in patients with chronic active hepatitis. Eur Respir J 1996;9:2691-6. PubMed
  7. Nakagawa A, Yamaguchi T, Takao T, Amano H. [Five cases of drug induced pneumonitis due to Sho-saiko-to or interferon-alpha or both]. Nippon Kyobu Shikkan Gakkai Zasshi 1995;33:1361-6.
  8. Miyazaki E, Ando M, Ih K, et al. [Pulmonary edema associated with the Chinese medicine shosaikoto]. Nihon Kokyuki Gakkai Zasshi 1998;36:776-80.
  9. Matsumoto T, Yamada H. Regulation of immune complexes binding of macrophages by pectic polysaccharide from Bupleurum falcatum L.: pharmacological evidence for the requirement of intracellular calcium/calmodulin on Fc receptor up-regulation by bupleuran 2
  10. Hattori T, Ito M, Suzuki Y. [Studies on antinephritic effects of plant components in rats (1). Effects of saikosaponins original-type anti-GBM nephritis in rats and its mechanisms]. Nippon Yakurigaku Zasshi 1991;97:13-21. PubMed
  11. Chang WC, Hsu FL. Inhibition of platelet activation and endothelial cell injury by flavan-3-ol and saikosaponin compounds. Prostaglandins Leukot Essent Fatty Acids 1991;44:51-6. PubMed
  12. Kato M, Pu MY, Isobe K, et al. Characterization of the immunoregulatory action of saikosaponin-d. Cell Immunol 1994;159:15-25. PubMed
  13. Ushio Y, Oda Y, Abe H. Effect of saikosaponin on the immune responses in mice. Int J Immunopharmacol 1991;13:501-8. PubMed
  14. Hirayama, C., Okumura, M., Tanikawa, K., and et al. A multicenter randomized controlled clinical trial of Shosaiko-to in chronic active hepatitis. Gastroenterol Jpn 1989;24(6):715-719. PubMed
  15. Hiai S, Yokoyama H, Nagasawa T, and et al. Stimulation of the pituitary-adrenocortical axis by saikosaponin of Bupleuri radix. Chemical and Pharmaceutical Bulletin (Tokyo) 1981;29(2):495-499. PubMed

Medication overviews come from MedlinePlus (NIH); supplement label data from the NIH Dietary Supplement Label Database. Content is written and reviewed by licensed HelloPharmacist pharmacists — see our data sources and editorial standards.

Pharmacist Counseling Corner

Taking Bupleurum and Nivolumab, Relatlimab-rmbw Together: Common Questions

Is it safe to take Bupleurum with Nivolumab, Relatlimab-rmbw?
We do not list a known interaction between Bupleurum and Nivolumab, Relatlimab-rmbw. That does not guarantee the combination is risk-free, so confirm with your pharmacist or doctor — especially if you take other medications or have a health condition.
Do Bupleurum and Nivolumab, Relatlimab-rmbw have any of the same side effects?
Yes — our sources link each of them separately to 5 of the same effects. That is not an interaction: neither changes how your body handles the other. It does mean that if one of those effects turns up, it can be harder to tell which one is behind it. They are listed on this page with the source behind each.
Does Bupleurum interact with any other medications?
Yes. Bupleurum has 327 documented drug interactions in our database — Nivolumab, Relatlimab-rmbw is simply not one of them. If you take anything else, it is worth checking each one; they are all listed on this page.

Written and reviewed by the HelloPharmacist editorial staff. Our editorial policy

Still Have a Question About Nivolumab, Relatlimab-rmbw and Bupleurum?

Our pharmacists answer your medication & supplement questions — free.

Ask a pharmacist

This information is for education only and is not a substitute for professional medical advice. Always check with your pharmacist or doctor before starting, stopping, or combining supplements and medications.